Jefferies Global Healthcare Conference
Logotype for Olema Oncology Inc

Olema Oncology (OLMA) Jefferies Global Healthcare Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Olema Oncology Inc

Jefferies Global Healthcare Conference summary

18 Nov, 2026

Pipeline and trial milestones

  • Palazestrant, a complete estrogen receptor antagonist with a 14-day half-life, is the lead asset; OPERA-01 monotherapy in 2L/3L is expected to read out in Q1, while 1L OPERA-02 with Kisqali is enrolling well and reads out later.

  • OP-3136 is a KAT6 inhibitor being studied in breast cancer with fulvestrant and palazestrant; monotherapy activity was also seen in castration-resistant prostate cancer.

  • OP-3136 with NUBEQA is starting in castration-resistant prostate cancer; earliest data expected by year-end 2027.

OPERA-01 rationale and design

  • Phase II median PFS was 7.3 months in ESR1-mutant and 5.5 months in ESR1 wild-type patients; OPERA-01 tests PFS in each population as a separate endpoint.

  • Management expects a 2–3-month control-arm PFS; eligibility excluded prior chemotherapy in advanced disease and required at least 6 months on the last prior regimen without progression.

  • Management said a wild-type benefit below 2 months could matter if statistically significant; the trial was powered for a minimally clinically meaningful benefit, with more wild-type than mutant patients supporting detection of a smaller difference.

  • In ESR1-mutant disease, management cited roughly 2 months of PFS extension as clinically meaningful; greater efficacy could differentiate palazestrant, while oral dosing avoids fulvestrant injections.

Market opportunity and commercial plans

  • Management estimated the ESR1-mutant market at $2B and ORSERDU sales at $600M–$800M annually, citing persistent unmet need and patients’ preference for oral options that can delay chemotherapy and avoid injections.

  • If OPERA-01 is positive and enables filing and launch, the U.S. plan is to file and launch; outside the U.S., filing is possible, but launch and promotion would require a collaborator.

  • Management sees OPERA-01 as potentially establishing the market for OPERA-02, a 1L opportunity it characterized as $10B+.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Olema Oncology